AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Stock Information for Avita Medical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avita Medical Inc.

AVITA Medical to Announce Third Quarter 2026 Financial Results
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
AVITA Medical to Announce Second Quarter 2026 Financial Results
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
AVITA Medical to Host Investor Webinar Briefing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.